Very well done and informative. I truly appreciate the Drug process in entirety being broken down into sections that are easy to comprehend. It is obvious the speakers were chosen for their knowledge.
I am really glad to have course offered by california university . Its really helpful for me. And i am thankful to all lecturer, and teachers to explain overall drug development process.\n\nThank you!
por Diego R•
This wasn't really great, it is a recording of several seminar presentations that were recorded several years ago, for this, the landscape has changed but the content hasn't, also, as this was planned for a in person presentation, the format is not optimal for a MOOC.
por Francisco M•
Me ha gustado bastante, he aprendido mucho con el curso. Aún así hay un aspecto que me afecta y es que s habla muy poco de la legislación a nivel europeo y eso hace que me sea menos util para mi formación.
por Matthew L•
Week 3 lectures were not as in-depth as hoped and filled with too many personal anecdotes for the time allowed. Much more could have been said if these had been skipped.
por Kayla A C•
Would be nice to update this course. The slides are from 2013 and I am listening in 2020. A lot has changed in the pharmaceutical market since in that time.
por Nikolai W•
The name of the course should be something a la 'Clincal trials and drug admistration agencies'. It is not the development of a drug.
por Mrunmai D M•
it was a great learning with coursera. it was indeed an informative course and glad hearing the prominent and experienced speakers
por Krithika S K N•
Was informative. The lectures could have been more structured and slides more detailed.
por Adrija C•
US- centric course. The content in week 3 was not well explained and felt rushed.
por Aneesh T G•
More emphasis on the filing and submissions and approvals need to be there
por Carolina S V•
Weeks 1 and 2 are great, but the classes of week 3 need more organization.
por Damien V•
good up to phase 2 (included). Phase 3 and after was less informative
por Brian M•
It's from 2013. Good overview but time for an update.
por Miguel M V•
would like an specialization on this matter
por Budupula K•
I gained knowledge
por Sofia B J•
por rahul r•
por DR. A G•
por Dale G Y•
Had hoped to hear a better description of the types of trials and more about the Regulators' logic in deciding what trials a drug must have - PK for ANDA? BE for ANDA? P1 and P3 for 505B2? Does PK=P1? These topics are useful. Need to define these options and explain the reason for using them for different scenarios. That's part of what I expected from Drug Development.
The lecture style of second half was difficult. More structure, clear pronunciation, less random thoughts about unexplained topics.
por Mohamed T H•
Phase 1 was explained nicely. But phase 2 description was unclear with some diagrams with not much context and a lot of acronyms thrown around. Did not learn a lot about phase 3 either. The presentation slides were very busy like the previous course.
por Malamati V•
I felt like the lectures were not so organized as far as their material is concerned. I also found the overall course more "business-oriented" than actually educational.
por Alejandro G•
The course was not structured as an online course. the slides were quite boring and some of the speakers were not enthusiastic
por Arash Y•
Presentation slides and sound quality is at its lowest.
por Maria B•
The course is not prepared for online course
por Benoit E•
A lot too much bla bla on the Phase iv part